Results 91 to 100 of about 422,566 (340)
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane+33 more
wiley +1 more source
Building Bridges across Cultures: Engaging in the Practice of Citizen Diplomacy [PDF]
The mission of the World Affairs Council of Oregon is to “broaden public awareness and understanding of international affairs and to engage Oregonians with the world.” The Council offers over forty public programs with experts and world leaders, hosts ...
Martinez, Clara
core +1 more source
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar+35 more
wiley +1 more source
A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen+14 more
wiley +1 more source
Duniway Middle School Counseling Center [PDF]
This presentation on the Duniway Middle School Counseling Center was given by Kelsey Chance as part of her Kemper Internship during ...
Chance, Kelsey
core +1 more source
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Student Dynamo Accepts Challenge [PDF]
Chipo Dendere ’08 completed an internship at the Carter Center last summer.
Thompson, Beth Rogers
core +1 more source
STEP Category: InternshipsThis is presentation of my STEP Signature Project through the Ohio State University. I participated in the Fisher College of Business's Summer Global Internship Program in Madrid, Spain for a duration of 8 weeks throughout the ...
Kall, Amanda
core